leadf
logo-loader
viewChampignon Brands Inc.

Champignon Brands announces changes to strengthen its corporate governance, management

The company says its plans include recruiting a new CFO, chief general counsel, and senior VP of communications

Champignon Brands Inc. -
Champignon Brands says its recent moves will emphasize transparency, full and accurate public reporting, plus operational readiness

Champignon Brands Inc (CSE:SHRM) (OTCQB:SHRMF) (FRA:496) reported that its management and governance is undergoing “comprehensive change at the top“ that will extend to the company's practices.

Champignon Brands said it is doing so in order to emphasize transparency, full and accurate public reporting plus operational readiness to “meet the accelerating, pandemic-drive demand for its clinical services.”

These changes include:

  • The company’s previously announced appointment of a new board chair, CEO, and new vice-chair
  • Recruiting a new CFO, chief general counsel, and senior vice president of investor and public communications
  • Its intention to expand its board with additional outside directors to be drawn from business and science
  • A re-designed website to facilitate proper access to current information by investors and the wider public

READ: Champignon Brands is making a scientific case for psychedelic medicine

The current board for Champignon Brands consists of Dr Roger McIntyre, chair and CEO; Bill Wilkerson, vice-chair; Matt Fish, president and secretary; and Jerry Habuda. Former director Gareth Birdsall has resigned effective November 23.

Champignon Brands is emerging as a leader in the burgeoning field of psychedelic medicine by pursuing the development and commercialization of rapid onset treatments capable of improving health outcomes, such as depression and post-traumatic stress disorder (PTSD), as well as substance and alcohol use disorders.

As one of the first psychedelic companies to go public, its network of ketamine clinics complements its sharp focus on research and development.

Its strategic approach establishes a differentiated platform with operating treatment clinics in the US and Canada that also facilitate research and development of a wide range of therapeutic and medical applications of psilocybin, the psychoactive ingredient in mushrooms.

Contact Sean at [email protected]

Quick facts: Champignon Brands Inc.

Price: 0.89 CAD

CSE:SHRM
Market: CSE
Market Cap: $70.54 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Champignon Brands Inc. named herein, including the promotion by the Company of Champignon Brands Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Champignon Brands charts course for success with acquisitions and a name change

Champignon Brands (CSE: SHRM- OTCQB: SHRMF) CEO Dr Roger McIntyre joined Steve Darling from Proactive Vancouver with news the company is changing its name to Apotheosis, which means the high point of development. McIntyre discusses the thinking behind the change, plus acquisitions and other...

on 06/22/2020

2 min read